Maribel Rodriguez-Torres

Summary

Publications

  1. ncbi request reprint On the cusp of change: new therapeutic modalities for HCV
    Maribel Rodriguez-Torres
    Fundación de Investigación de Diego San Juan, Puerto Rico Avenida de Diego 359, San Juan, Puerto Rico
    Ann Hepatol 9:123-31. 2010
  2. doi request reprint Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    J Hepatol 58:663-8. 2013
  3. doi request reprint Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    Curr Opin Infect Dis 26:50-7. 2013
  4. doi request reprint Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient
    Maribel Rodriguez-Torres
    Fundación de Investigación, Avenida Muñoz Rivera, 998 Rio Piedras, Puerto Rico 00927
    Expert Rev Anti Infect Ther 10:1117-28. 2012
  5. doi request reprint Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico 00927, USA
    HIV Clin Trials 13:142-52. 2012
  6. ncbi request reprint  Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients
    Maribel Rodriguez-Torres
    Fundación de Investigación, Rio Piedras, Puerto Rico
    Ann Hepatol 11:450-63. 2012
  7. ncbi request reprint Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Gastroenterol 40:358-66. 2006
  8. ncbi request reprint Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 51:161-7. 2006
  9. ncbi request reprint Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Virol 38:32-8. 2007
  10. doi request reprint Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009

Detail Information

Publications11

  1. ncbi request reprint On the cusp of change: new therapeutic modalities for HCV
    Maribel Rodriguez-Torres
    Fundación de Investigación de Diego San Juan, Puerto Rico Avenida de Diego 359, San Juan, Puerto Rico
    Ann Hepatol 9:123-31. 2010
    ..Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment...
  2. doi request reprint Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    J Hepatol 58:663-8. 2013
    ..We assessed the safety, tolerability, antiviral activity, and pharmacokinetics of sofosbuvir plus pegylated-interferon (PegIFN)/ribavirin (RBV) in a 28-day, dose-ranging trial in treatment-naïve patients infected with genotype 1 HCV...
  3. doi request reprint Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    Curr Opin Infect Dis 26:50-7. 2013
    ..Understanding DDIs between HIV antiretroviral therapy (ART) and the DAAs in development is important to assure the best management of the HIV/HCV coinfected individuals...
  4. doi request reprint Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient
    Maribel Rodriguez-Torres
    Fundación de Investigación, Avenida Muñoz Rivera, 998 Rio Piedras, Puerto Rico 00927
    Expert Rev Anti Infect Ther 10:1117-28. 2012
    ....
  5. doi request reprint Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico 00927, USA
    HIV Clin Trials 13:142-52. 2012
    ..The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials...
  6. ncbi request reprint  Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients
    Maribel Rodriguez-Torres
    Fundación de Investigación, Rio Piedras, Puerto Rico
    Ann Hepatol 11:450-63. 2012
    ..Response to hepatitis C treatment is known to differ by race; and, limited data suggests by ethnicity as well. A lower efficacy of HCV therapy in Latinos has been observed; whether higher doses may improve the response is unknown...
  7. ncbi request reprint Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Gastroenterol 40:358-66. 2006
    ..Hepatitis C virus (HCV) infection is prevalent in Latinos. There is some evidence that progression to cirrhosis is more rapid...
  8. ncbi request reprint Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 51:161-7. 2006
    ..Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients...
  9. ncbi request reprint Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Virol 38:32-8. 2007
    ..We examined the safety and efficacy of peginterferon alfa-2a (peg-IFNalpha-2a) plus ribavirin (RBV) in 41HCV/HIV-coinfected patients non-responsive to prior IFN treatment...
  10. doi request reprint Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously...
  11. ncbi request reprint High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 50:634-9. 2005
    ..A combination of esomeprazole, tetracycline, and metronidazole is effective for eradication of H. pylori in patients allergic to penicillin, for both first-line treatment and failures of prior treatment...